Literature DB >> 2302112

Corneal surface irregularities and episodic pain in a patient with mucolipidosis IV.

N J Newman1, T Starck, K R Kenyon, S Lessell, I Fish, E H Kolodny.   

Abstract

Mucolipidosis IV is a lysosomal storage disease characterized by prominent involvement of the corneal epithelium. A 5-year-old boy with mucolipidosis IV experienced recurrent episodes of severe ocular pain, tearing, and ipsilateral facial flushing. This was suggestive of reflex sympathetic dystrophy, a syndrome of pain and sympathetic hyperactivity. The examination revealed marked corneal surface irregularities, corresponding to massive accumulations of intracytoplasmic storage material in the epithelium. Episodic pain in patients with mucolipidosis IV is an important symptom, presumably reflecting the distinctive corneal ultrastructural abnormality in this disease.

Entities:  

Mesh:

Year:  1990        PMID: 2302112     DOI: 10.1001/archopht.1990.01070040103041

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

Review 1.  Mucolipidosis type IV: an update.

Authors:  Kazuyo Wakabayashi; Ann Marie Gustafson; Ellen Sidransky; Ehud Goldin
Journal:  Mol Genet Metab       Date:  2011-06-16       Impact factor: 4.797

2.  Constitutive achlorhydria in mucolipidosis type IV.

Authors:  R Schiffmann; N K Dwyer; I A Lubensky; M Tsokos; V E Sutliff; J S Latimer; K P Frei; R O Brady; N W Barton; E J Blanchette-Mackie; E Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 3.  The role of TRPMLs in endolysosomal trafficking and function.

Authors:  Kartik Venkatachalam; Ching-On Wong; Michael X Zhu
Journal:  Cell Calcium       Date:  2014-10-28       Impact factor: 6.817

4.  Mice, double deficient in lysosomal serine carboxypeptidases Scpep1 and Cathepsin A develop the hyperproliferative vesicular corneal dystrophy and hypertrophic skin thickenings.

Authors:  Xuefang Pan; Yanting Wang; Torben Lübke; Aleksander Hinek; Alexey V Pshezhetsky
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.